Online inquiry

IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4726MR)

This product GTTS-WQ4726MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL21 gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001207006.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 59067
UniProt ID Q9HBE4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4726MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11628MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MGD-013
GTTS-WQ9616MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ12978MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ1989MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ13936MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-2810
GTTS-WQ12688MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ10515MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY3002813
GTTS-WQ10625MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3303560
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW